ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

1541

शेयरों में रैंक #19257
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
शेयर मूल्य
$0.3799409
अंतिम समन्वयन: 2026-10-20
मार्केट कैप
$159.21M
बदलाव (1 दिन)
-0.34%
बदलाव (1 वर्ष)
-71.63%
देश
CN
व्यापार ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)

श्रेणी

Healthcare
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) के लिए लाभांश इतिहास
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (स्टॉक चिन्ह: 1541) ने कुल 0 लाभांश भुगतान किए।
सभी लाभांशों का योग (स्टॉक स्प्लिट्स के लिए समायोजित) है: 0.00
लाभांश यील्ड (TTM): 0
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) के लिए 2026 से 2026 तक के लाभांश भुगतान
वार्षिक लाभांश भुगतान
वर्ष लाभांश (स्टॉक स्प्लिट समायोजित) परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
सभी लाभांश भुगतानों की सूची
वर्ष लाभांश परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
समान कंपनियों या प्रतिस्पर्धियों के लाभांश भुगतान
कंपनी लाभांश भुगतान की संख्या देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL